Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

National Early Warning Score

- PMLiVE

Europe Celebrates the Heart of Healthcare Decision-Making as Laboratory Medicine Professionals Take Centre Stage

Today, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) proudly marks European Laboratory Day, celebrating the professionals at the heart of healthcare decision making. Across Europe, laboratories will...

EatMoreFruit

- PMLiVE

Bridging the gap: Should pharma step up as public health campaign funding declines?

With the decline in UK public health campaign funding, we have explored the unique opportunity presented to the pharmaceutical industry to step forward and do more to support the nation’s...

Say Communications

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

UK government’s AMR study highlights importance of appropriate antibiotic use

The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam

- PMLiVE

UKHSA releases list of pathogens posing ‘greatest risk’ to public health

The agency has listed 24 pathogen families where preparedness efforts are most needed

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

Making an Impact at the Agents of Change Summit

Medscape Public Health is hitting the road to attend the public health conference Agents of Change. As part of their commitment to making an impact in public health, Medscape is...

Medscape Education

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

- PMLiVE

NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

More than 100 patients are expected to be eligible for the treatment every year

- PMLiVE

NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

Systemic mastocytosis affects approximately one in every 10,000 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links